Kaletra

Kaletra is a medication used to treat HIV/AIDS. Its active ingredient includes a combination of lopinavir and ritonavir. These are antiretroviral drugs that help to control the virus in the body. Kaletra is also known by its generic name, Lopinavir/ritonavir. It is important for prolonging and improving the life of people with HIV/AIDS.

Kaletra Price

The common price range for Kaletra lies between £3.23 – £3.67 per pills. This range is subject to the size of the packaging and the potency of the contained ingredients (60 or 360 mg).

Check price

Description

Composition and Formulations

Kaletra contains two active ingredients: lopinavir and ritonavir. Lopinavir acts as an antiretroviral agent, while ritonavir functions as a pharmacokinetic enhancer. The medication is available in tablet, oral solution, and oral powder forms. Each 200 mg/50 mg tablet consists of 200 mg lopinavir and 50 mg ritonavir. The oral solution provides 80 mg lopinavir and 20 mg ritonavir per milliliter.

Mechanism of Action

Lopinavir, a protease inhibitor, inhibits HIV-1 protease, an enzyme vital for viral replication. Ritonavir inhibits the cytochrome P450 3A (CYP3A) enzymes, increasing lopinavir plasma concentrations. This enhanced bioavailability and prolongs the antiretroviral effect of lopinavir, optimizing HIV suppression.

Indications for Use

Kaletra is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 14 days and older when prescribed in combination with other antiretroviral agents. It is suitable for use in both treatment-naïve and experienced patients with no documented lopinavir resistance.

Recommended Dosage

The standard adult dosage for Kaletra tablets is two 200 mg/50 mg tablets twice daily, taken with or without food. For pediatric patients, the dosage varies based on body weight or body surface area and is administered twice daily. For patients unable to swallow tablets, the oral solution or oral powder may be considered.

Administration Instructions

Tablets should be swallowed whole and not chewed, broken, or crushed. The oral solution must be measured with a suitable syringe or dosing cup. Oral powder is mixed with soft food or liquid before ingestion. Consistency in dosing time is crucial to maintaining effective drug levels.

Drug Interactions

Kaletra significantly interacts with various drugs metabolized by CYP3A enzymes. Coadministration with drugs such as rifampin, St. John’s Wort, and certain antiarrhythmics is contraindicated. Other antiretrovirals, antifungals, and anticonvulsants may require dosage adjustments due to altered plasma concentrations.

Storage Conditions

Tablets should be stored at room temperature, between 20°C to 25°C (68°F to 77°F), protected from moisture. The oral solution should be refrigerated at 2°C to 8°C (36°F to 46°F) and used within two months if stored at room temperature. Oral powder should be protected from moisture and stored at room temperature.

Cautions and Contraindications

Kaletra is contraindicated in patients with known hypersensitivity to any of its components. Caution is advised in patients with hepatic impairment due to an increased risk of side effects. Reformulation should be done carefully for patients on concurrent medications that may increase lopinavir or ritonavir levels.

Adverse Reactions

Common adverse effects include diarrhea, nausea, vomiting, and elevated lipid levels. Pancreatitis, hepatotoxicity, and severe skin reactions are serious but less common. Patients should report any unusual symptoms promptly for evaluation and management.

Special Populations Considerations

For pregnant women, Kaletra is categorized under pregnancy category C; the potential benefits should justify the potential risk to the fetus. In breastfeeding mothers, either the drug or breastfeeding needs to be discontinued due to the risk of HIV transmission and potential adverse effects. Elderly patients may require dosage adjustments based on renal clearance.

Monitoring and Laboratory Tests

Regular monitoring of liver function tests, lipid profiles, and blood counts is recommended during treatment with Kaletra. Viral load and CD4 counts should also be periodically evaluated to assess therapeutic efficacy and adherence.

Patient Counseling Information

Patients should be advised on the importance of adherence to their medication regimen and informed about potential side effects. They should understand how to manage missed doses and the importance of regular medical follow-ups. Inform patients about drug interactions and discuss any concurrent medications they may be taking.

Clinical Trial Results

In clinical trials, Kaletra demonstrated significant virologic suppression and immunologic improvement in both treatment-naïve and experienced patients. Studies have shown durable efficacy over several years, with a favorable resistance profile compared to other protease inhibitors.
Other